The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome

International Journal of Clinical Practice

Volumn 61, Issue 11, 2007, Pages 1942-1948

  Thoenes, M ^a   Oguchi, A ^b   Nagamia, S ^b   Vaccari, C S ^b   Hammoud, R ^b   Umpierrez, G E ^b   Khan, B V ^b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; SLO NIACIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BRACHIAL ARTERY; CAROTID ARTERY OBSTRUCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; DRUG DOSE TITRATION; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; INFLAMMATION; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUSTAINED DRUG RELEASE;

ADULT; ANTILIPEMIC AGENTS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CAROTID ARTERIES; CHOLESTEROL, HDL; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; ENDOTHELIUM; FEMALE; HUMANS; INFLAMMATION; MALE; METABOLIC DISEASES; MIDDLE AGED; NIACIN; PROSPECTIVE STUDIES; SYNDROME; TREATMENT OUTCOME; TUNICA INTIMA;

EID: 35348902493     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01597.x     Document Type: Article

References (27)

1. Grundy SM, Hansen B, Smith SC Jr. et al. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004 109 : 551 6.
2. Tuomilehto J, Lindstrom J, Qiao Q. Strategies for the prevention of type 2 diabetes and cardiovascular disease. EHJ Suppl 2005 7 (Suppl. D D18 22.
3. Lakka HM, Laaksonen DE, Lakka TA et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002 288 : 2709 16.
4. National Cholesterol Education Program. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001 285 : 2486 97.
5. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005 365 : 1415 28.
6. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome. An AHA/NHLBI Scientific Statement. Circulation 2005 112 : 2735 52.
7. Sutherland J, McKinnley B, Eckel RH. The metabolic syndrome and inflammation. Metab Syndr Rel Disord 2004 92 : 347 55.
8. Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2003 24 : 278 301.
9. Castelli WP, Garrison RJ, Wilson PWF et al. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA 1986 256 : 2835 8.
10. Kuvin JT, Dave DM, Sliney KA et al. Effects of extended release niacin on lipoprotein particle size, distribution and inflammatory markers in patients with coronary artery disease. Am J Cardiol 2006 98 : 743 5.
11. Kuvin JT, Ramet ME, Patel AR et al. A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am Heart J 2002 144 : 165 72.
12. Benjo AM, Maranh RC, Coimbra RS et al. Accumulation of chylomicron remnants and impaired vascular reactivity occur in subjects with isolated low HDL cholesterol: effects of niacin treatment. Atherosclerosis 2006 187 : 116 22.
13. Grundy SM, Vega GL, McGovern ME et al. for the Diabetes Multicenter Research Group. Efficacy, safety and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial (ADVENT). Arch Intern Med 2002 162 : 1568 76.
14. Hodis HN, Mack WJ, LaBree L et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998 128 : 262 9.
15. Taylor AJ, Sullenberger LE, Lee HJ et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004 110 : 3512 7.
16. Al Shaer MH, Jerome WP. The appropriateness of nicotinic acid derivative use in patients with the metabolic syndrome: insights from the ARBITER 2 study. Am J Cardiol 2006 98 : 275 6.
17. Allison MA, Tiefenbrun J, Langer RD, Wright CM. Atherosclerotic calcification and intimal medial thickness of the carotid arteries. Int J Cardiol 2005 103 : 98 104.
18. Salonen JT, Korpela H, Salonen R, Nyssonnen K. Ultrasonographic manifestations of common carotid atherosclerosis in elderly eastern Finnish men. Prevalence and associations with cardiovascular diseases and risk factors. Arterioscler Thromb 1994 10 : 1631 40.
19. Corretti MC, Anderson TJ, Benjamin EJ et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery. J Am Coll Cardiol 2002 39 : 257 65.
20. Hoeks AP, Brands PJ, Smeets FA, Reneman RS. Assessment of the distensibility of the superficial arteries. Ultrasound Med Biol 1990 16 : 121 8.
21. Bianchini E, Faita F, Gemignani V, Giannoni M, Demi M. The assessment of flow mediated dilation of the brachial artery. Comput Cardiol 2006 33 : 509 12.
22. Weverling-Rijnsburger AWE, Jonkers IJA, van Exel E et al. High-density vs low-density lipoprotein cholesterol as the risk factor for coronary artery disease and stroke in old age. Arch Intern Med 2003 163 : 1549 4.
23. Toth PP. High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies. Am J Cardiol 2005 96 (Suppl. 50K 8. PL, Berge KG, Wenger NK et al. Fifteen year mortality in Coronary Drug Project patients: long term benefit with niacin. J Am Coll Cardiol 1986 8 : 1245 55.
24. Brown BG, Zhao X-Q, Chait A et al. Simvastatin and niacin, antioxidant vitamins, or the combination for prevention of coronary disease. N Engl J Med 2001 345 : 1583 92.
25. Ridker PM, Cannon CP, Morrow D et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy - Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) - investigators. N Engl J Med 2005 352 : 20 8.
26. Westphal S, Borucki K, Taneva E et al. Adipokines and treatment with niacin. Metabolism 2006 55 : 1283 5.
27. Kastelein JJP, van Leuven SI, Burgess L et al. for the RADIANCE 1 Investigators. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Eng J Med 2007 356 : 1620 30.